High intensity focused ultrasound for the treatment of localized prostate cancer: Efficacy and impact on sexual function;Traitement par ultrasons focalisés du cancer localisé de la prostate: Résultats carcinologiques et pronostic sexuel

Andrologie

Volumn 13, Issue 3, 2003, Pages 242-251

  Gelet, Albert ^a   Poissonnier, Laura ^a   Chapelon, Jean Yves ^b   Bouvier, Raymonde ^a   Rouviere, Olivier ^a   Lyonnet, Denis ^a   Dubernard, Jean Michel ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Erectile dysfunction; Focused ultrasound; Localized prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER SURVIVAL; CONFERENCE PAPER; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PROSTATE CANCER; QUESTIONNAIRE; SEXUAL FUNCTION; SEXUAL INTERCOURSE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; ULTRASOUND;

EID: 0142124374     PISSN: 11662654     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03034878     Document Type: Conference Paper

References (50)

1. ARTERBERY V.E., WALLNER K., ROY J., FUKS Z.: Shortterm morbidity from CT-planned transperineal 1-125 prostate implants. Int. J. Radiat. Oncol. Biol. Phys., 1993, 25: 661-667.
2. BAGSHAW M.A., COX R.S., RAY G.R.: Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr., 1988, 7:47-60.
3. BANKER F.L.: The preservation of potency after external beam irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1988, 15:219-220.
4. BEARD C.J., LAMB C., BUSWELL L. et al.: Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1998, 41: 257-262.
5. CHAPELON J.Y., MARGONARI J., THEILLERE Y. et al.: Effects of high-energy focused ultrasound on kidney tissue in the rat and the dog. Eur. Urol., 1992, 22: 147-152.
6. CHAPELON J.Y., MARGONARI J., VERMIER F., GORY F., ECOCHARD R., GELET A.: In vivo effects of high intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res., 1992, 52: 6353-6457.
7. CHAUSSY C., THUROFF S.: High intensity focused ultrasound in prostate cancer: results after 3 years. Mol. Urol., 2000, 4:179-182.
8. CHAUSSY C., THUROFF S.: Results and side effects of High intensity focused ultrasound in localized prostate cancer. J. Endourol., 2001, 15: 437-440.
9. CHAVRIER F., CHAPELON J.Y., GELET A., CATHIGNOL D.: Modeling of high-intensity focused ultrasound-induced lesions in the presence of cavitation bubbles. J. Acoust. Soc. Am., 2000, 108: 432-440.
10. CHINN D.M., HOLLAND J., CROWNOVER R.L., ROACH M. III: Potency following high-dose three-dimensional conformal radiotherapy and the impact of prior major urologic surgical procedures in patients treated for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1995, 33:15-22.
11. CROOK J., ESCHE B., FUTTER N.: Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function the patient's perspective. Urology, 1996, 47: 387-394.
12. D'AMICO A.V., WHITTINGTON R., KAPLAN I. et al.: Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37:1053-1058.
13. D'AMICO A.V., WHITTINGTON R., MALKOWICZ S.B. et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J. Am. Med. Ass., 1998, 280: 969-974.
14. D'AMICO A.: Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology, 2001, 58: 78-82.
15. FUKUNAGA-JOHNSON N., SANDLER H.M., MC LAUGHLIN P.W. et al.: Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1997, 38: 311-317.
16. GELET A., CHAPELON J.Y., MARGONARI J. et al.: High intensity focused ultrasound: Experimentation on canine prostate. J. Endourol., 1993, 7: 249-253.
17. GELET A., CHAPELON J.Y., MARGONARI J. et al.: Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur. Urol., 1996, 29: 174-183.
18. JONLER M., RITTER M.A., BRINKMANN R., MESSING E.M., RHODES P.R., BRUSKEWITZ R.C.: Sequelae of definitive therapy for prostate cancer localized to the pelvis. Urology, 1994, 14: 876-882.
19. KUPELIAN P., KATCHER J., LEVIN H. et al.: External beam radiotherapy versus radical prostatectomy for clinical stage T1-T2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J. Sci. Am., 1997, 3: 78-87.
20. LILLEBY W., FOSSA S.D., WAEHRE H.R., OLSEN D.R.: Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys., 1999, 43: 735-743.
21. LITWIN M.S., HAYS R.D., FINK A. et al.: Quality-of-life outcomes in men treated for localized prostate cancer. J. Am. Med. Ass., 1995, 273: 129-135.
22. LYONS J.A., KUPELIAN P.A., MOHAN D.S., REDDY C.A., KLEIN E.A.: Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology, 2000, 55: 85-90.
23. MADALINSKA J.B., ESSINK-BOT M.L., DE KONING H.J., KIRKELS W.J., VAN DER MAAS P.J.: Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J. Clin. Oncol., 2001, 19: 1587-1588.
24. MANTZ C.A., SONG P., FARHANGI E. et al.: Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37: 551-557.
25. NGUYEN L.N., POLLACK A., ZAGARS G.K.: Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology, 1998, 51: 991-997.
26. PEARSON J.D., CARTER H.B.: Natural history of changes in prostate specific antigen in early stage prostate cancer. J. Urol., 1994, 152: 1743-1747.
27. PEREZ C.A., LEE H.K., ANASATASIOS G., LOCKETT M.A.: Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 1994, 28: 811-819.
28. PISANSKY T.M., KAHN M.J., BOSTWICK D.G.: An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer, 1997, 79: 2154-2161.
29. POTOSKY A.L., LEGLER J., ALBERTSEN P.C. et al.: Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J. Natl. Cancer Inst., 2000, 92: 1582-1592.
30. POTTERS L., CHA C., OSHINSKY G., VENKATRAMAN E., ELEFSKY M., LEIBEL S.: Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J. Sci. Am., 1995, 5: 301-306.
31. PRESTIDGE B.R., HOAK D.C., GRIMM P.D., RAGDE H., CAVANAGH W., BLASKO J.C.: Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37: 31-39.
32. RAGDE H., ELGAMAL A.A., SNOW P.B. et al.: Ten-year disease free survival after transperineal sonography-guided iodine125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer, 1998, 83: 999-1001.
33. RAGDE H., BLASKO J.C., GRIMM P.D. et al.: Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer, 1997, 80: 442-453.
34. ROACH M. III, CHINN D.M., HOLLAND J., CLARKE M.: A pilot survey of sexual function and quality of life following 3D conformal radiotherapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1996, 35: 869-874.
35. ROUVIERE O., LYONNET D., RAUDRANT A. et al.: MRI Appearance of prostate following Transrectal HIFU ablation of localized cancer. Eur. Urol., 2001, 40: 265-274.
36. SHARKEY J., CHOVNICK S.D., BEHAR R. et al.: Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. Urology, 1998, 51: 796-803.
37. SHIPLEY W.U., PROUT G.R. Jr., COACHMAN N.M. et al.: Radiation therapy for localized prostate carcinoma: Experience at the Massachusetts General Hospital (1973-1981). Natl. Cancer Inst. Monogr., 1988, 7: 67-73.
38. STOCK R.G., STONE N.N.: The effect of pronostic factors on therapeutic outcome following transperineal prostate brachytherapy. Sem. Surg. Oncol., 1997, 13: 454-460.
39. STOCK R.G., STONE N.N., KAO J., IANNUZZI C., UNGER P.: The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy. Cancer, 2000, 89: 1829-1834.
40. STOCK R.G., STONE N.N., DE WYNGAERT J.K., LAVAGNINI P., UNGER P.D.: Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer, 1996, 77: 2386-2392.
41. STOKES S.H.: Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int. J. Radiat. Oncol. Biol. Phys., 2000, 47: 129-136.
42. nd meeting of ASCO. J. Clin. Oncol., 1996, 15: 252 (Abstr).
43. TALCOTT J.A., RIEKER P., CLARK J.A.: Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study. J. Clin. Oncol., 1998, 16: 275-283.
44. WALLNER K., LEE H., WASSERMAN S., DATTTOLI M.: Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37: 565-569.
45. WALLNER K., ROY J., ZELEFSKY M., FUKS Z., HARRISON L.: Short-term freedom from disease progression after I-125 prostate implantation. Int. J. Radiat. Oncol. Biol. Phys., 1994, 30: 405-409.
46. WALLNER K., ROY J., HARRISON L.: Tumour control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J. Clin. Oncol., 1996, 14: 449-453.
47. WILDER R.B., CHOU R.H., RYU J.K. et al.: Potency preservation after three-dimensional conformal radiotherapy for prostate cancer. Am. J. Clin. Oncol., 2000, 23: 330-333.
48. ZELEFSKY M.J., WALLNER K.E., LING C.C. et al.: Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J. Clin. Oncol., 1999, 17: 517-522.
49. ZELEFSKY M.J., HOLLISTER T., RABEN A., MATTHEWS S., WALLNER K.E.: Five-year biochemical outcome and toxicity with transperineal CT-planned permanent 1-125 prostate implantation for patients with localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2000, 47: 1261-1266.
50. ZELEFSKY M.J., COWEN D., FUKS Z. et al.: Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer, 1999, 85: 2460-2468.